Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (Q47685354)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. |
scientific article |
Statements
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program (English)
P McLaughlin
A J Grillo-López
R Levy
M S Czuczman
M E Williams
M R Heyman
I Bence-Bruckler
C A White
F Cabanillas
V Jain
A D Ho
J Lister
K Wey
D Shen
B K Dallaire
1 August 1998